Another study has also shown that the levels of GPX4 and mTORC1 are higher in NSCLC cells, and inhibition of these molecules provides a promising strategy to overcome lapatinib resistance in vivo (19). The gene discussed is GPX4; the disease is non-small cell lung carcinoma.